Sign in
CompletedNo phase

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Status
Completed
People taking part
5 people enrolled
Started
11 Jun 2025
Ended
31 Mar 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Re-Timer glasses
  • Placebo Device
Record updated
7 April 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 18-65 years old
  • Irritable Bowel Syndrome based on Rome IV diagnostic criteria
  • Mild to severe IBS symptom severity based on IBS-SSS greater than or equal to 75 17
  • Late chronotype based on the Munich Chronotype Questionnaire (Corrected Midpoint of Sleep > 4:00h) 18 Exclusion Criteria
  • Subject that are pregnant or plan to become pregnant
  • Night shift workers or people who have crossed more than 2 time zones in the previous 4 weeks
  • Regular use of medications that affect intestinal permeability, and/or endogenous melatonin including metoclopramide, NSAIDs, beta blockers, antibiotics, psychotropic medications, hypnotics and exogenous melatonin products during 4 weeks prior to the study
  • Any major organ disease - known renal impairment, diabetes, liver disease, or significant cardiac failure (NY classification stage III/IV), inflammatory bowel disease or celiac disease per chart review and/or medical history
  • Diagnosis of narrow angle glaucoma or retinal disorders or demonstrated symptoms indicative of these diagnosis during the eligibility screening
  • Moderate to severe depression (score ≥ 21 or any endorsement of suicidal intent on the Beck Depression Inventory) 19
  • Sleep apnea (score high risk in 2 or more categories of the Berlin Questionnaire) 20
  • Restless leg syndrome (score ≥ 15 on the IRLS Study Group Rating Scale) 21
  • Inability or unwillingness of subject to sign an informed consent

Where in United States

  • Medical University of South CarolinaCharleston, United States

About the trial

What the trial wants to find out

The purpose of this research study is to assess whether morning bright light therapy (BLT) using a wearable device called a Re-Timer could potentially improve Irritable Bowel Syndrome (IBS) symptoms and decrease intestinal permeability (leaky gut). Morning bright light therapy will be administrated through a safe-wearable glasses device called a Re-Timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light.

The 2 groups in the trial

  • Re-Timer Device (Bright Light Therapy)Treatment being tested

    Morning bright light therapy will be administrated through a safe wearable device called a Re-timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light. The device emits light at a higher wavelength than the UV range and has a UV filter for added safety. Subjects will be asked to wear the glasses for one hour each morning per day for 7 days a week. They will wear the device for a total of 14 days to receive the full therapeutic effect. Additionally, subjects will be asked to complete the light therapy the first hour of being awake and remain indoors while using the device. Participants will be informed that they can wear the device freely throughout their home or work environment but should avoid activities that could potentially be harmful (i.e., driving, contact sports, operating heavy machinery).

    Treatment: Re-Timer glasses

  • Placebo device (non Bright Light Therapy)Placebo, for comparison

    Subjects will be asked to wear glasses that do not provide Bright Light Therapy for one hour each morning per day for 7 days a week as recommended by the manufacturer. They will wear the device for a total of 14 days to receive the full therapeutic effect. Additionally, subjects will be asked to complete the light therapy the first hour of being awake and remain indoors while using the device. Participants will be informed that they can wear the device freely throughout their home or work environment but should avoid activities that could potentially be harmful (i.e., driving, contact sports, operating heavy machinery).

    Treatment: Placebo Device

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 April 2026